All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD2 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human CD2. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD2 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Colorectal cancer.
CAR Construction : Fig.1 Lack Fc g receptor (FcyR) IIIA signaling induced by CD2-binding molecule 1 (a deglycosylated CD2-binding molecule) as compared to the FcyRIIIA signaling of anti-CD2 Abl (e.g., siplizumab (MED 1-507)). |
CAR Construction : Fig.2 The comparable ability of CD2-binding molecule 1 (a deglycosylated CD2-binding molecule) and anti-CD2 Abl (e.g., siplizumab) to inhibit the activation of CD4+/CD25+ T cells. |
CAR Construction : Fig.3 The ability of CD2-binding molecule 1 (a deglycosylated CD2- binding molecule) to inhibit NK cell activation (Induction of CD69 expression on NK cells) as compared to anti-CD2 Abl (e.g., siplizumab) in allogenic mixed lymphocyte reaction (MLR). |
CAR Construction : Fig.4 Natural NK cell cytotoxicity. Purified NK cells were pre incubated no antibody, 0.001-10 μg/mL anti-CD2 Abl (e.g., siplizumab) or 0.001-10 μg/mL of CD2-binding molecule 2, 3, or 4 (Fc-silent (FcS) anti-CD2 IgG antibodies) for 30 minutes or two days followed by addition of HLA class I- target cells (SPI-801). |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD2 (Siplizumab) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-0120ZP2145). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION